Lorenza Rimassa· @LorenzaRimassa · X·· 2 天前评分70
正文 · 机器翻译
EileenO’Reilly 在 #ESMO26 介绍了 AMPLIFY-7P 随机 II 期研究：评估已切除肿瘤的 #KRAS-mutant #PDAC 患者使用 camupepimut 作为辅助治疗 #ESMOAmbassadors @myESMO
843 浏览 · 17 赞 · 6 转发 · 1 回复
会议摘要
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683P按 NSCLC, metastatic 对上
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org帖内回复
- Santhosh Ambika@RenoHemonc
@LorenzaRimassa @myESMO
来源：Lorenza Rimassa · x.com